Baicalin and myricetin were characterized by their ability to inhibit EMT, reduce expression of PI3K/Akt/mTOR and markers of RA-FLS aggressiveness, as well as suppress production of IL-6, IL-8, and metalloproteinases [4,52]. This evidence concerns the gene IL6 and rheumatoid arthritis.